Key result
Lipid-lowering therapies and lifestyle changes are reviewed to summarize recent guideline recommendations for treating dyslipidaemia in prediabetic and diabetic patients.
Answers are grounded in this paper and cite their sources.
Review demonstrates current lipid management strategies in prediabetic and diabetic patients, highlighting risk-tailored therapies to reduce cardiovascular morbidity.
Dyslipidaemia is a modifiable risk factor commonly associated with diabetes mellitus and prediabetes, with a major impact on the early development of atherosclerotic cardiovascular disease. Various studies have tried to identify the key treatment targets, their optimal values according to patients' CV risk, and the most efficient yet safe therapeutic agents which, alongside lifestyle changes, would improve lipid levels and reduce cardiovascular mortality and morbidity. Currently, there are multiple pharmacologic options that can be used in the management of dyslipidaemia, such as statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, n-3 polyunsaturated fatty acids or fibrates, to name only a few, while many other are under development. In the current setting of a continuously increasing population of patients with metabolic disorders, this review aims to summarise current knowledge regarding lipid disorders and the recommendations of recent guidelines in treating dyslipidaemia in patients with diabetes mellitus or prediabetes.
No takes yet. Share an insight, caveat, or question.
Gaiţă et al. (2024) conducted a review in Dyslipidaemia in diabetes mellitus and prediabetes. Lipid-lowering therapies (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, n-3 polyunsaturated fatty acids, fibrates) and lifestyle changes was evaluated. Lipid-lowering therapies and lifestyle changes are reviewed to summarize recent guideline recommendations for treating dyslipidaemia in prediabetic and diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: